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Abstract
Despite an increase in the number of molecular epidemiological studies conducted in recent years to evaluate the
association between human papillomavirus (HPV) and the risk of breast carcinoma, these studies remain inconclusive. Here
we aim to detect HPV DNA in various tissues from patients with breast carcinoma using the method of HPV capture
combined with massive paralleled sequencing (MPS). To validate the confidence of our methods, 15 cervical cancer samples
were tested by PCR and the new method. Results showed that there was 100% consistence between the two methods.DNA
from peripheral blood, tumor tissue, adjacent lymph nodes and adjacent normal tissue were collected from seven malignant
breast cancer patients, and HPV type 16(HPV16) was detected in 1/7, 1/7, 1/7and 1/7 of patients respectively. Peripheral
blood, tumor tissue and adjacent normal tissue were also collected from two patients with benign breast tumor, and 1/2, 2/
2 and 2/2 was detected to have HPV16 DNA respectively. MPS metrics including mapping ratio, coverage, depth and SNVs
were provided to characterize HPV in samples. The average coverage was 69% and 61.2% for malignant and benign samples
respectively. 126 SNVs were identified in all 9 samples. The maximum number of SNVs was located in the gene of E2 and E4
among all samples. Our study not only provided an efficient method to capture HPV DNA, but detected the SNVS, coverage,
SNV type and depth. The finding has provided further clue of association between HPV16 and breast cancer.
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Introduction
Breast cancer is the second most common type of cancer
worldwide, with the highest prevalence rate among women in the
world and 1/8 of women suffer from breast cancer during lifetime
[1]. Hereditary mutations (such as BRAC1/2, TP53, PTEN, and
STK11) cause only about 5% of breast cancer case [2]. Infectious
factors was responsible for 18% of human cancers and it is well
accepted that human breast cancer is highly associated with
environmental factors, such as diet, source of water, virus,
radiation [3,4,5,6]. Breast tumorigenesis might be promoted by
viral infection. High-risk HPV such as HPV type 16(HPV16),
HPV type 18(HPV18) were associated with cervical cancer,
anogenital cancers and cancers of other organs [7,8]. Factors that
favor a small proportion of HPV16 infections to progress to cancer
are still poorly understood, but the genetic variation has implicated
a role of HPV16 in previous study [9–10].
There were increasing studies reporting on the involvement of
HPV DNA in breast cancer in recent years, but the conclusions
remained to be highly controversial. Di Lonardo et al. [11] first
reported the detection of HPV16 DNA in 29% of 17 patients with
breast cancer by polymerase chain reaction (PCR). De Villiers et
al. [12] found HPV DNA in 86% of breast cancers (25/29) and in
69% of the corresponding nipple sample (20/29). HPV11 was
detected as the most prevalent type, followed by HPV type 6. Only
12% of the samples displayed signal of HPV16, while HPV18 was
failed to be found in all samples. HPV infection was also reported
in breast cancer by some other studies [13–15]. However, several
other studies failed to detect any signals of HPV in breast cancer
cells [16–17]. Beyond that, Wrede et al. [18] recruited 95 women
suffering from breast cancer and screened HPV 6b, 11, 13, 16, 18,
30, 31, 32, 33, 45, and 51. , but they didn’t find any signal of HPV
infection.
Previous studies were mostly based on PCR based approach, in
which unique primers targeting HPV genes were designed to
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screen the existence of virus DNA. This strategy is easy to access
and screen in large number of samples, but limited in sensitivity
and specificity, thus probably contribute to so many controversial
studies. Here, we adopted the sequence capture and MPS method
to detect the signal of HPV DNA fragment which also provided
unique opportunity to study HPV variations in its whole genome
level. The study validated the efficiency of the novel method in
breast cancer and discovered HPV DNA can be detected in blood,
tumor tissue, adjacent lymph nodes and adjacent normal tissue of
breast cancer patient, furthermore analyze the variations among
them.
In this study, we not only provided an efficient method to
capture HPV DNA in tissues of breast cancer patients, but also
found HPV SNVs difference in the samples. This provided new
insight in studying the association between HPV infection and
breast cancer.
Material and Methods
Material
9 sets of breast cancer samples were collected respectively from
9 female patients and received surgery at the department of
vascular and endocrine surgery, Xijing hospital, the Fourth
Military Medical University, China, between October 2010 and
October 2011 (Table S1). Exclusion criteria were: 1. systemic
therapy prior to surgery, 2. bilateral breast cancer, 3. metastatic or
recurrent disease, 4. cancer of other origin. Adjuvant therapy was
based on current NCCN (National Comprehensive Cancer
Network) guidelines. In addition, In order to evaluate the accuracy
of our method, 15cervical cancer samples were also collected from
Xijing hospital (Table S2). Written Informed consents were
obtained from each patient. All aspects of this study were reviewed
and approved by the institutional review board at the Xijing
Hospital and BGI.
The 9 sets of samples were respectively from 7 malignant breast
cancer patients whose ages ranged from 37 to 85 and 2 benign
breast cancer patients. For malignant breast cancer, each set
included 4 types of tissues (tumor tissue, adjacent normal tissue,
lymph nodes and blood). For benign patients, each set included 3
types of tissues (tumor tissue, para-carcinoma tissue and blood).
The blood samples were collected before surgery and the tissue
samples were preserved in liquid nitrogen with programmed
freezing in 1 hour after isolation. All samples were used to detect
signals of HPV DNA.
All 34 read datasets are accessible through the NCBI Short
Read Archive (http://www.ncbi.nlm.nih.gov/Traces/sra/) under
the accession number SRA124368 (SRP035570).
HPV probes design and HPV genome enrichment and
sequencing
Full-length HPV genome of 17 types (6,11,16,18,31,33,35,
39,45,52,56,58,59,66,68,69,82)were used to design the HPV
probes by MyGenostics (MyGenostics, Baltimore, MD). Sequenc-
ing libraries of 170 bp insert size were constructed following the
instruction of Illumina. Genomic DNA was sheared to around
150 bp–200 bp DNA fragments by Covaris E-210 (Covaris, Inc.,
Woburn, MA). These fragments were purified, end blunted, ‘‘A’’
tailed, and adaptor ligated. 10 cycles of PCR were performed after
Figure 1. Overview of the workflow. It shows the pipeline of experimental process and bioinformatics process for this study.
doi:10.1371/journal.pone.0090343.g001
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size selection in 2% agarose gel. The concentration of libraries was
quantified by Bioanalyzer 2100 (Agilent Technologies, Santa
Clara, CA).The hybridization process was carried according to
MyGenostics GenCapTM Target Enrichment Protocol. Libraries
were hybridized with HPV probes(Including 17 high-risk types of
HPV) at 65uC for 24 hours and then washed to remove un-
captured fragments. The eluted fragments were amplified by 18
cycles of PCR to generate libraries for sequencing. Libraries were
quantified and preceded to 101 cycles’ paired-end index sequenc-
ing using the Illumina HiSeq 2000 sequencer according to
manufacturer’s instructions (Illumina Inc., San Diego, CA).
HPV Fragment detection
The 100 bp paired-end reads were preceded into bioinformatics
process. The paired-end reads which contained the signals of HPV
were picked out, and then the mapping ratio, depth, coverage and
SNVs on HPV genome of these reads would be obtained. The
details of the bioinformatics process are presented as follows
(Figure 1).
Raw data filter. Low quality reads (a read with more than
50% low quality value bases whose quality value is less than 5) and
duplication reads, as well as adaptor contaminated reads, were
firstly removed. The remained clean reads were obtained for
subsequent analysis.
Sequence Mapping. Clean reads were mapped to human
genome (NCBI build 37, HG19) and HPV genome
(6,11,16,18,31,33,35,39,45,52,56,58,59,66,68,69,82) using SOAP2
(-l 40 -v 5 -r 1) [19].
Detection of HPV DNA Signals. If a paired-end reads were
not able to map onto human genome but were able to map onto
HPV genome, it would be reported as signals of HPV DNA for
subsequent analysis.
The coverage, depth and mapping ratio on HPV genome were
calculated based on these reported reads. A sample was considered
HPV positive if the Coverage of the sample on HPV genome was
higher than 50%.
coverage~covered region=genome size:
Covered_region means the size of the covered region on HPV
genome by reported reads; genome_size here means the size of the
HPV genome. We also calculated average depth and normalized
depth.
Average depth~TNBC=Genome size
Normalized depth~Average depth=Effective reads number
TNBC means the number of bases mapped on HPV genome.
Effective reads number means the total number of reads after the
process of Raw data filter.
For one certain sample, the depth reflects the reads number
covered on the HPV16 genome in raw data. Normalized depth
was defined to make the depth comparable among samples with
different data quantities.
The SNV of HPV genome was called based on the alignment
results of the reported reads using soapsnp (-r 0.0005 -e 0.001 -t -u
-L 100) [20].
The criterions of quality control of SNVs calling were: 1.The
Quality score of consensus genotype is not smaller than 20; 2. Count of
uniquely mapped second best base/Count of uniquely mapped best base .0.2;
3. Count of uniquely mapped second best base is not less than 2.
Results
HPV detection in cervical cancer samples
It’s well accepted that HPV plays an important role in cervical
cancer. We obtained 15 cervical cancer samples which included 5
negative samples and 10 positive samples by PCR diagnosis. We
carried on the HPV capture in these 15 samples, and found 100%
accuracy in the result with our method. (Table S2)
Overview of HPV detection in breast cancer
We analyzed 9 sets of samples collected respectively from 7
malignant breast cancer patients and 2 benign breast tumor
patients. HPV16 (K02718.1) was the only HPV type detected in
all of the samples. For malignant breast cancer, HPV16 was found
only in the set of samples from patient C080. We also found
HPV16 DNA in 1/2, 2/2, 2/2 of patients with benign breast
tumor, in blood, tumor and adjacent normal tissue respectively.
MPS metrics and clinical data were reported in Table S1.
Additionally, we tried to detect the HPV integrations using the
method of HIVID [21], but all samples showed negative results.
SNVs of HPV16 identification in various samples
To further analyze any discrepancies among various tissues, we
tried to identify the SNV pattern of HPV16 in all the samples
(Table S3). For the set samples of C080, the normal and blood
tissue had more SNVS in the region of E2, E4, L1 and L2. For the
set samples of T009 and T007, the normal and tumor tissue had
more SNVS in these regions. The region of E2 and E4 had more
SNVS among all samples (Table S4).
Then we surveyed the SNV number of transition and
transversion in different tissue types of all patients. Four tissue
types of C080 had the same trend that there were more
transversions than transitions. The normal and tumor tissue of
T009 had the contrary trend with set samples of C080(Table 1).
Then we surveyed the synonymous and non-synonymous SNVs
(Table S5). Most of the SNVs belonged to the non-synonymous
mutations. The proportion of nonsynonymous mutations in genes
of L1,L2,E1,E2,E5 and E6 was 76%,75%,93%,75.7%,100%,
100%, While the proportion of synonymous mutation in genes of
E7 and E4 was 80%,100%.The SNVS number of transition and
Table 1. SNV Information.
Sample ID Transition Transversion Total
C080 11 13 24
C080C 4 5 9
C080L 3 6 9
C080N 7 13 20
T007C 9 6 15
T007N 6 9 15
T009 1 8 9
T009C 7 6 13
T009N 7 5 12
Total 55 71 126
This table revealed that the distribution of SNVS of transition and transversion
in different samples.
doi:10.1371/journal.pone.0090343.t001
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transversion was 30 and 57 among the SNVS of nonsynonymous
(Table 2),but was 47 and 6 in synonymous mutations. It had the
similar trend that the number of synonymous mutations was less
than the non-synonymous mutations in benign and malignant
samples (Table S6).
We also performed comparisons between malignant and benign
samples for the same tissue type and found that almost every tissue
type from malignant sample set C080 and benign sample set T009
shared some common SNVs (Figure 2, Table S7).
In patient C080 with malignant tumor, the numbers of SNV
were 24, 9, 20 and 9, respectively in blood, tumor tissue, and
adjacent normal tissue and lymph tissues. 3 common SNVs were
identified in all tissues which were located in the position 178(E6,
Nonsynonymous), 846(E7, Synonymous), 3448(E2, Nonsynon-
ymous; E4, Synonymous) of HPV genome (Figure 3a). Accord-
ingly, in patient T009 with benign tumor, the numbers of SNV
were 9, 13 and 12 respectively in blood, tumor and adjacent
normal tissue. All tissues shared 2 SNVs located in the position
178(E6, Nonsynonymous), 3523(E4, E2, Synonymous) of HPV
genome (Figure 3b). Besides, the numbers of SNV were both 15 in
two tissue types (tumor, adjacent normal) of T007, while most of
common SNVs were located in the region of 2000 bp–4500 bp.
To pinpoint the SNV variations among the different tissue types
in C080, we compare the tumor SNVs with other tissues and
identify one SNV was tumor specific (5926, L1, Synonymous).
Discussion
There are enough evidences for the relationships between HPV
and cervical cancer [22], but the relationship between HPV and
breast cancer still remains elusive. Even in the study with positive
results, the detected subtypes tend to be various. Many studies
suggest viral oncogenesis as an etiological factor for breast cancer,
while there are also studies coming out of negative result for HPV.
Thus it remains controversial.
The PCR based approach has dominated the previous
molecular investigations of HPV in breast cancer, and made
significant contributions in some discoveries. Although convenient
in common molecular laboratories, it lacks enough sensitivity for
further sequence analysis and stability which to some extent
revealed by so many controversial reports.
MPS technology has been widely used to study the origin,
selection and evolution of virus in recent years. The novel method
we introduced here combined MPS with virus-target probe
capture, as well as high-performance bioinformatics algorithm
which are capable to detect signals of target virus and analyze its
sequences. MPS makes large-scale paralleled detection of virus
signal possible and enables us to reconstruct the virus genome in
base-pair resolution, and the capture technology greatly enriched
the interested region thus reduced the cost. Our method is not only
able to detect virus signals in multiple tissues, but also has the
ability to detect the signals of multiple viruses at the same time in a
single run with high specificity and sensitivity. To avoid the
potential false positive signals introduced by contamination reads,
we set strict filtering of 50% of HPV genome is covered by at least
one read for a sample to be called as HPV positive. This cut off
was adopted to judge the existence of HPV in our 15 cervical
tumors, and showed a 100% consistency with PCR result.
HPV16 DNA was detected in several tissue types of both
malignant and benign samples from breast cancer patients using
our new method. Analyzing the coverage, depth distribution,
mapping ratio and SNVs of virus genome are helpful for us to find
some clue about the association between HPV16 and breast
cancer.
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Traditionally HPV was thought to only infect cutaneous and
mucosal tissues but not transmissible via blood. Some discoveries
of HPV DNA in blood had brought this notion into question.
Chen AC. et al. [23] screened HPV DNA in peripheral blood by
PCR in 180 healthy male blood donors in age from 18–76 and
found 15 donors (5.8%) with positive result. In another study
Andreas Widschwendter et al. also found HPV16 DNA in blood
(5/11) from breast cancer patient [24]. In our study, HPV16 DNA
was detected in blood of both malignant breast cancer patient (1/
7) and patient with benign tumor (1/2).Although we detected
HPV DNA in blood of breast cancer patient, the role of HPV16
remains to be elucidated.
The tissue type which included more SNVS had significant
difference between malignant and benign samples. More SNVS
were included in the blood and normal tissue of C080, while the
tumor and normal tissues of T007 and T009 included more SNVs.
Most of SNVS were located in the E2 region. The papillomavirus
E2 protein is required for viral replication and regulates both viral
transcription and replication, and therefore plays a central role in
the viral life cycle. In addition, E2 is also important for repressing
oncoprotein transcription. The mutation on E2 region may have
an effect on these aspects in order to keep adaptive [25–26].
Furthermore, common SNVs of malignant cancer sample set
C080 (E6, 178, nonsynonymous; E7, 846, synonymous; E2, 3448,
Figure 2. Contrast of SNVs between benign samples and malignant samples. There are three pairs of circles close together in this figure.
The color of green, blue and grey represents the tumor tissue, blood and adjacent normal tissue respectively. In every pair of circle, the inner circle
represents malignant sample C080 and the outer circle represents benign sample T009. Each red point is the position of a SNV and the rectangular
black box surround the SNVs which share the same position in several samples.
doi:10.1371/journal.pone.0090343.g002
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nonsynonymous) and that of benign tumor sample set T009 (E6,
178, nonsynonymous; E2, 3523, synonymous) were significantly
discrepant. The SNVS of 178,846 had been identified as the most
frequent sequence variation site by previous studies and they had
been identified as markers of the Asian lineage [27,28].Previous
study has also found the discrete regions of 647–846 show the most
frequently observed substitution in HPV16 E7 open reading frame
[29]. When compared HPV SNV patterns of different tissues from
the same patient (Figure 3a, Figure 3b), we identified the SNV (L1,
5926,synonymous) in C080C.The SNV of 5926 which only existed
in the C080C could not lead to change of the protein coding.
We carried on the SNVS categorization according to the
synonymous and non-synonymous mutations. The total SNVS
number was 126. We got more than 126 SNVS when performing
the analysis of synonymous and nonsynonymous mutations. Some
SNVS located in two genes region was the cause of the
phenomenon. For example the SNVS located in the E4 gene
could also located in the E2 gene. The synonymous mutations do
not change the protein coding and are not affected by natural
selection,while nonsynonymous mutations alter the protein
sequences and can be affected by natural selection [30–31]. Most
of the nonsynonymous mutations were located in genes of L1, L2,
E1 and E2.The genes of L1 and L2 encode the structural capsid
proteins, and mutations of these genes may indicate that these
amino acid changes are beneficial to accommodate the human
papillomavirus to its environment [32]. For example SNV of
position 6241(L1, Nonsynonymous) existed in six samples (C080,
C080C, C080N, T007N, T009, T009C), which changed the
protein coding. This change might lead to selective advantage of
HPV16 for escaping from immune recognition by the host
immune system. The ability of E1 and E2 to complex with each
other appears to be essential for efficient viral DNA replication
and E6 gene of the high risk group is known to be oncogene
[25,26].These mutations of the three genes may have the
association with keeping functional advantage. Viral gene E4
expression reflects viral replication, and E7 is known as oncogene
[28].The synonymous mutations were inclined to the two genes.
The changes may keep the adaption of HPV16 by base
substitution. The SNV pattern was more inclined to the transition
in the synonymous mutations, but the pattern was more inclined to
the transversion in the nonsynonymous mutations. The phenom-
enon had the similar trend with previous study [33].
Improvements of awareness in patient and physician about
necessity in treatment for HPV infection might be the preferred
strategy for clinical prevention. Wang T et al. [34] proposed that
prophylactic HPV vaccines for cervical cancer may also reduce the
development of breast cancer in women and the repression of viral
oncogene expression can prevent the growth or survival of breast
cancer cells.
In our study, we not only found several samples which had high
coverage and depth of HPV, but also detected significant SNVs
difference in distribution, number and type. The finding implies
that a possible causal role of HPV infection in breast cancer
carcinogenesis could not be ruled out. We believe the finding has
provided further clue of association between HPV16 and breast
cancer. Certainly, there is a need of further study to confirm the
role of HPV16 in breast cancer.
Supporting Information
Table S1 Summary of clinical data and sequencing analysis.
(XLSX)
Table S2 Supplementary Results and validation of 15 cervical
cancer samples.
(XLS)
Figure 3. The display of SNVs in a sample set. A. SNVs for sample set of C080; B. SNVs for sample set of T009. The locations of the genes are
shown in different colors. Each red point is the position of a SNV and the rectangular black box surround the SNVs which share the same position in
several samples. Genomic positions are numbered. A. It is cancer tumor, blood, lymph nodes and adjacent normal tissue from the outside to the
inside. B. There are three green circles and it is tumor tissue, blood and adjacent normal tissue from the outside to the inside.
doi:10.1371/journal.pone.0090343.g003
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Table S3 SNVs of all the HPV positive samples.
(XLS)
Table S4 The distribution of SNV in HPV gene.
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Table S5 The information of whether the SNV is synonymous
or nonsynonymous.
(XLS)
Table S6 The distribution of SNVS of Nonsynonymous and
synonymous in benign and maligant samples.
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Table S7 The common SNVs of the same tissue type.
(XLS)
Acknowledgments
We would like to thank Xi Jing hospital for providing the samples and
thank the colleagues in BGI-shenzhen for sequencing and bioinformatics
assistance.
Author Contributions
Conceived and designed the experiments: LW TW JC CH XQZ.
Performed the experiments: TW WYL HZ GW QY CYH. Analyzed the
data: XZ TW GW WYL XL YL XHZ. Contributed reagents/materials/
analysis tools: CH JZ YZ HH JF. Wrote the paper: XZ TWWYL GW XL
JW CYH.
References
1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA
Cancer J Clin 55: 74–108.
2. Campeau PM, Foulkes WD, Tischkowitz MD (2008) Hereditary breast cancer:
new genetic developments, new therapeutic avenues. Hum Genet 124: 31–42.
3. Armstrong B, Doll R (1975) Environmental factors and cancer incidence and
mortality in different countries, with special reference to dietary practices.
Int J Cancer 15: 617–631.
4. Parkin DM (2006) The global health burden of infection-associated cancers in
the year 2002. Int J Cancer 118: 3030–3044.
5. Antonsson A, Bialasiewicz S, Rockett RJ, Jacob K, Bennett IC, et al. (2012)
Exploring the prevalence of ten polyomaviruses and two herpes viruses in breast
cancer. PLoS One 7: e39842.
6. Silva RG Jr, da Silva BB (2011) No evidence for an association of human
papillomavirus and breast carcinoma. Breast Cancer Res Treat 125: 261–264.
7. zur Hausen H (2009) Papillomaviruses in the causation of human cancers - a
brief historical account. Virology 384: 260–265.
8. Acevedo-Nuno E, Gonzalez-Ojeda A, Vazquez-Camacho G, Balderas-Pena Luz
Ma A, Moreno-Villa H, et al. (2004) Human papillomavirus DNA and protein
in tissue samples of oesophageal cancer, Barrett’s oesophagus and oesophagitis.
Anticancer Res 24: 1319–1323.
9. Schiffman M, Rodriguez AC, Chen Z, Wacholder S, Herrero R, et al (2010) A
population-based prospective study of carcinogenic human papillomavirus
variant lineages, viral persistence, and cervical neoplasia. Cancer Res
70:3159–3169.
10. Gheit T, Cornet I, Clifford GM, Iftner T, Munk C, et al. (2011) Risks for
persistence and progression by human papillomavirus type 16 variant lineages
among a population-based sample of Danish women. Cancer Epidemiol
Biomarkers Prev 20: 1315–1321.
11. Di Lonardo A, Venuti A, Marcante ML (1992) Human papillomavirus in breast
cancer. Breast Cancer Res Treat 21: 95–100.
12. de Villiers EM, Sandstrom RE, zur Hausen H, Buck CE (2005) Presence of
papillomavirus sequences in condylomatous lesions of the mamillae and in
invasive carcinoma of the breast. Breast Cancer Res 7: R1–11.
13. Damin AP, Karam R, Zettler CG, Caleffi M, Alexandre CO (2004) Evidence for
an association of human papillomavirus and breast carcinomas. Breast Cancer
Res Treat 84: 131–137.
14. Kroupis C, Markou A, Vourlidis N, Dionyssiou-Asteriou A, Lianidou ES (2006)
Presence of high-risk human papillomavirus sequences in breast cancer tissues
and association with histopathological characteristics. Clin Biochem 39: 727–
731.
15. Gumus M, Yumuk PF, Salepci T, Aliustaoglu M, Dane F, et al. (2006) HPV
DNA frequency and subset analysis in human breast cancer patients’ normal
and tumoral tissue samples. J Exp Clin Cancer Res 25: 515–521.
16. Lindel K, Forster A, Altermatt HJ, Greiner R, Gruber G (2007) Breast cancer
and human papillomavirus (HPV) infection: no evidence of a viral etiology in a
group of Swiss women. Breast 16: 172–177.
17. de Cremoux P, Thioux M, Lebigot I, Sigal-Zafrani B, Salmon R, et al. (2008)
No evidence of human papillomavirus DNA sequences in invasive breast
carcinoma. Breast Cancer Res Treat 109: 55–58.
18. Wrede D, Luqmani YA, Coombes RC, Vousden KH (1992) Absence of HPV 16
and 18 DNA in breast cancer. Br J Cancer 65: 891–894.
19. Li R, Yu C, Li Y, Lam TW, Yiu SM, et al. (2009) SOAP2: an improved ultrafast
tool for short read alignment. Bioinformatics 25: 1966–1967.
20. Li R, Li Y, Fang X, Yang H, Wang J, et al. (2009) SNP detection for massively
parallel whole-genome resequencing. Genome Res 19: 1124–1132.
21. Li W, Zeng X, Lee NP, Liu X, Chen S, et al. (2013) HIVID: An efficient method
to detect HBV integration using low coverage sequencing. Genomics 102: 338–
344.
22. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, et al. (2000)
Evidence for a causal association between human papillomavirus and a subset of
head and neck cancers. J Natl Cancer Inst 92: 709–720.
23. Chen AC, Keleher A, Kedda MA, Spurdle AB, McMillan NA, et al. (2009)
Human papillomavirus DNA detected in peripheral blood samples from healthy
Australian male blood donors. J Med Virol 81: 1792–1796.
24. Widschwendter A, Brunhuber T, Wiedemair A, Mueller-Holzner E, Marth C
(2004) Detection of human papillomavirus DNA in breast cancer of patients with
cervical cancer history. J Clin Virol 31: 292–297.
25. Masterson PJ, Stanley MA, Lewis AP, Romanos MA (1998) A C-terminal
helicase domain of the human papillomavirus E1 protein binds E2 and the DNA
polymerase alpha-primase p68 subunit. J Virol 72: 7407–7419;
26. Blakaj DM, Fernandez-Fuentes N, Chen Z, Hegde R, Fiser A, et al. (2009)
Evolutionary and biophysical relationships among the papillomavirus E2
proteins. Front Biosci 14: 900–917.
27. Shang Q,Wang Y, Fang Y, Wei L, Chen S,et al(2011)Human Papillomavirus
Type 16 Variant Analysis of E6, E7, and L1 Genes and Long Control Region in
Identification of Cervical Carcinomas in Patients in Northeast China,
JOURNAL OFCLINICALMICROBIOLOGY, 49:2656–2663;
28. Smith B, Chen Z, Reimers L, van Doorslaer K, Schiffman M, et al(2011)
Sequence Imputation of HPV16 Genomes for Genetic Association Studies,Plos
one 6:e21375.
29. Liu X, Liu GB, Pang ZJ, Xing FQ (2005) Sequence polymorphism of human
papillomavirus type 16 E7 in cervical cancer]. Di Yi Jun Yi Da Xue Xue Bao 25:
1272–1275.
30. Kimura M (1977) Preponderance of synonymous changes as evidence for the
neutral theory of molecular evolution. Nature 267: 275–276.
31. Miyata T, Miyazawa S, Yasunaga T (1979) Two types of amino acid
substitutions in protein evolution. J Mol Evol 12: 219–236.
32. Buck CB, Cheng N, Thompson CD, Lowy DR, Steven AC, et al. (2008)
Arrangement of L2 within the Papillomavirus Capsid. J Virol 82: 5190–5197
33. Sun M, Gao L, Liu Y, Zhao Y, Wang X, et al(2012) Whole Genome Sequencing
and Evolutionary Analysis of Human Papillomavirus Type 16 in Central China.
PLoS ONE 7(5): e36577
34. Wang T, Chang P, Wang L, Yao Q, Guo W, et al. (2012) The role of human
papillomavirus infection in breast cancer. Med Oncol 29: 48–55.
Detection of HPV DNA in Breast Cancer Patients
PLOS ONE | www.plosone.org 7 March 2014 | Volume 9 | Issue 3 | e90343
